glp 1 semaglutide Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity Microdosed GLP-1 (Semaglutide)

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies.

Powered by Peptide

Suggested Use: Take 1 capsule 3 times daily, ideally before meals, as part of a balanced health routine

Mendelian Randomization (MR) was applied, primarily using the inverse variance weighted (IVW) method, to evaluate the causal relationship between T2D and SA

As GLP-1 receptor agonists, these peptide drugs mimic the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite [9]